1. Synthetic HLA-independent T cell receptors for cancer immunotherapy.
- Author
-
Simon S, Bugos G, and Riddell SR
- Subjects
- Antibodies, Humans, Immunotherapy, Receptors, Antigen, T-Cell genetics, Immunotherapy, Adoptive, Neoplasms genetics, Neoplasms therapy
- Abstract
CAR T cells are remarkably effective in hematologic malignancies, but tumor cells expressing low antigen levels can escape elimination. In Nature Medicine, Mansilla-Soto et al. design new chimeric receptors that link the variable regions of antibodies directly to T cell receptor chains and recognize tumor cells with improved antigen sensitivity., Competing Interests: Declaration of interests S.R.R. is a founder of Juno Therapeutics, now Juno/Bristol Myers Squibb, and a founder of and advisor to Lyell Immunopharma. S.R.R. has patents related to the field of chimeric antigen receptor-modified T cells and their use in immunotherapy., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF